Bullous pemphigoid associated with dipeptidyl peptidase‐4 inhibitor showing unfavorable outcomes despite immediate discontinuation of medication

We experienced two cases of dipeptidyl peptidase‐4 (DPP‐4) inhibitor‐associated bullous pemphigoid (BP) showing an unfavorable course despite its discontinuation. Clinicians should carefully monitor the course of DPP‐4 inhibitor‐associated BP even after withdrawal of DPP‐4 inhibitor therapy, especia...

Descripción completa

Detalles Bibliográficos
Autores principales: Shinohara, Yasutake, Iijima, Toshie, Sakurai, Shintaro, Jojima, Teruo, Ohira, Eriko, Hayashi, Shujiro, Usui, Isao, Igawa, Ken, Aso, Yoshimasa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7562854/
https://www.ncbi.nlm.nih.gov/pubmed/33088540
http://dx.doi.org/10.1002/ccr3.3047
Descripción
Sumario:We experienced two cases of dipeptidyl peptidase‐4 (DPP‐4) inhibitor‐associated bullous pemphigoid (BP) showing an unfavorable course despite its discontinuation. Clinicians should carefully monitor the course of DPP‐4 inhibitor‐associated BP even after withdrawal of DPP‐4 inhibitor therapy, especially in very elderly patients.

Ejemplares similares